On September 13, 2021 Immunocore Holdings Plc (Nasdaq: IMCR), a late-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious and autoimmune disease, reported that new data and analysis from the Company’s lead program, tebentafusp, and its proprietary soluble TCR bispecific ImmTAC platform will be presented at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress, which will be held virtually from September 16-21, 2021 (Press release, Immunocore, SEP 13, 2021, View Source [SID1234587701]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
ORAL PRESENTATION
Title: Early reduction in ctDNA, regardless of best RECIST response, is associated with overall survival (OS) on tebentafusp in previously treated metastatic uveal melanoma (mUM) patients
Abstract ID: 17570
Presenter: Alexander Shoushtari
Abstract & full data set available: Friday, 17 September 2021, 18:00 CEST
POSTER PRESENTATIONS
Title: Similar overall survival in tebentafusp-treated 2L+ metastatic uveal melanoma regardless of prior immunotherapy
Abstract ID: 1013P
Presenter: Joseph M. Piulats
Title: Demonstration of T cell redirection and immune activation in skin rash following tebentafusp treatment
Abstract ID: 1772P
Presenter: Ramon Stäger
Title: Characterization of cytokine release syndrome (CRS) following treatment with tebentafusp in previously untreated patients with metastatic uveal melanoma
Abstract ID: 1014P
Presenter: April Salama
Title: Characterization of liver function tests following tebentafusp in phase 3 randomized trial comparing tebentafusp with investigator’s choice in first line metastatic uveal melanoma (mUM)
Abstract ID: 1018P
Presenter: Bartosz Chmielowski
Title: Genomic correlates of clinical outcomes in patients with metastatic uveal melanoma (mUM) treated with tebentafusp (tebe)
Abstract ID: 1770P
Presenter: Luis de la Cruz Merino
Title: ImmTAC redirect exhausted tumor infiltrating T cells, an effect enhanced by pembrolizumab against PD-L1+ tumors
Poster #: 1016P
Presenter: Kristina Petrovic
Title: PRAME expression and ImmTAC TCR bispecific sensitivity in acute myeloid leukaemia in the presence and absence of the hypomethylating agent decitabine
Abstract ID: 853P
Presenter: Camille Britton-Rivet
The abstracts referenced above our available on the ESMO (Free ESMO Whitepaper) website.